Sarepta cuts 36% workforce, reports $513M Q2 revenue, agrees to ELEVIDYS black box warning

Sarepta Therapeutics, Inc.

Workforce reduction of ~36% (~500 employees); one-time charge of $32-37M in Q3 2025; annual cost savings of ~$400M.
Preliminary Q2 2025 net product revenue $513M: ELEVIDYS $282M, PMOs $231M; cash & investments ~$850M.
FDA requested black box warning for acute liver injury/failure in ELEVIDYS label; Sarepta agrees, resolving material issues for ambulant patients.
Pipeline reprioritized to focus on siRNA platform; most LGMD gene therapies paused, except SRP-9003 BLA expected H2 2025.
Executive changes: Ian Estepan as President/COO, Louise Rodino-Klapac as President R&D, Ryan Wong as CFO; Dallan Murray departs.

item 2.02item 2.05item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.